This is a demo store. No orders will be fulfilled.

Rifaximin - 10mM in DMSO, high purity , CAS No.80621-81-4(DMSO)

In stock
Item Number
R408980
Grouped product items
SKU Size
Availability
Price Qty
R408980-1ml
1ml
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$179.90

DNA/RNA Synthesis Inhibitors

View related series
Compound libraries (12325)

Basic Description

Synonyms (2S,​16Z,​18E,​20S,​21S,​22R,​23R,​24R,​25S,​26R,​27S,​28E)​-25-​(acetyloxy)​-​5,​6,​21,​23-​tetrahydroxy-​27-​methoxy-​2,​4,​11,​16,​20,​22,​24,​26-​octamethyl-​2,​7-​(Epoxypentadeca[1,​11,​13]​trienimino)​benzofuro[4,​5-​e]​pyrido[1,​2-​a]​benzimidazole
Specifications & Purity Moligand™, 10mM in DMSO
Biochemical and Physiological Mechanisms Rifaximin is a RNA synthesis inhibitor by binding the β subunit of the bacterial DNA-dependent RNA polymerase, used to treat traveler\'s diarrhea caused by certain bacteria.
Storage Temp Store at -80°C
Shipped In
Ice chest + Ice pads
This product requires cold chain shipping. Ground and other economy services are not available.
Grade Moligand™
Product Description

Information

Rifaximin Rifaximin is a RNA synthesis inhibitor by binding the β subunit of the bacterial DNA-dependent RNA polymerase, used to treat traveler's diarrhea caused by certain bacteria.
In vitro

Rifaximin (50 μM) reduces changes in the production of proinflammatory factors caused by LPS stimulation in IEC, such as TNF-α, IL-8, Rantes and PGE2 in normal intestinal epithelial cells. Rifaximin inhibits the LPS-induced cytokine and chemokine expression by suppressing NF-κB DNA-binding activity. Rifaximin (100 μM) effectively decreases the expression of TNFα, IL-8, MIP-3α and Rantes induced by LPS stimulation (100 μg/mL). Rifaximin binds the β subunit of the bacterial DNA-dependent RNA polymerase, inhibiting the initiation of chain formation in RNA synthesis. Rifaximin has a lower MIC against gram-positive bacteria, with an MIC90 at dosages ranging from 0.01 µg/mL to 0.5 µg/mL. Rifaximin has broad-spectrum activity against aerobic and anaerobic gram-positive and gram-negative microorganisms.

In vivo

Rifaximin is highly concentrated in the intestinal tract compared with rifampicin. Rifaximin treatment results in significant induction of PXR target genes in the intestine of hPXR mice, but not in wild-type and Pxr- mice. Rifaximin-mediated activation of human PXR, but not the other xenobiotic nuclear receptors constitutive androstane receptor, peroxisome proliferator-activated receptor (PPAR)alpha, PPARgamma, and farnesoid X receptor. Rifaximin could lead to PXR-dependent hepatocellular fatty degeneration as a result of activation of genes involved in lipid uptake, thus indicating a potential adverse effect of rifaximin on liver function after long-term exposure.
Cell Data

cell lines:NCI-H441 cells

Concentrations:

Incubation Time:

Powder Purity:≥97%

Names and Identifiers

Smiles COC1\C=C\OC2(C)OC3=C(C2=O)C4=C(C(=C3C)O)C(=C(NC(=O)\C(=C/C=C/C(C)C(O)C(C)C(O)C(C)C(OC(C)=O)C1C)C)C5=C4N=C6C=C(C)C=C[N]56)O
Molecular Weight 785.88

Certificates(CoA,COO,BSE/TSE and Analysis Chart)

C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:

Citations of This Product

Solution Calculators

Reviews

Customer Reviews

Shall we send you a message when we have discounts available?

Remind me later

Thank you! Please check your email inbox to confirm.

Oops! Notifications are disabled.